

8 May 2024

TRISTEL plc ("Tristel", the "Company", or the "Group")

Tristel™ ULT case study

Tristel ULT highlighted as novel method to simplify high-level disinfection for urological procedures

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, welcomes the publication of a white paper "Simplifying High-Level Disinfection for Urological Procedures: A Case Study" at the American Urological Association ("AUA") 2024 conference, the largest gathering of urologists in the world. In the paper, US urologist, Dr Matthew Allaway, highlights Tristel™ ULT in a case study, commenting on the product's ability to enable faster, simpler endocavitary probe processing for busy urology practices.





The paper which was released on 4 May 2024, highlights Tristel™ ULT as an alternative to conventional chemical soaking and misting products. In June 2023 the Food and Drug Administration ("FDA") created a new category of Class II medical device disinfectants titled "foam or gel chemical sterilant/high-level disinfectant" under which De Novo clearance for Tristel™ ULT was granted.

As referenced within Dr Allaway's study, Tristel™ ULT is recognised as a high level disinfectant ("HLD") and is effective against pathogens ranging from Human papillomavirus ("HPV") type 16 and type 18 to Mycobacterium terrae. Tristel™ ULT helps to address numerous bottlenecks that can impact workflow in a busy urology practice. One of the most time-consuming tasks is reprocessing medical devices between procedures. Chemical soaking and misting methods of HLD can damage probes and require complex workflows limiting the number of procedures clinicians can perform during a typical patient list. As the paper highlights:

"Unlike conventional germicidal agents, HLD with Tristel ULT does not require specialized equipment, plumbing, or electricity and can be performed at the point of use. Its substantially faster reprocessing time allows for high throughput—more procedures can be performed in less time compared to conventional disinfection methods."

Paul Swinney, CEO of Tristel, commented: "Our commercial partner, Parker Laboratories Inc., is presenting Tristel™ ULT alongside its range of ultrasonic gels and probe covers at multiple healthcare conferences this year. The most notable is the forthcoming American Prevention of Infection Congress ("APIC") in Texas in

June. We first announced our FDA approval at this same event held in Orlando last year. In our first 12 months in the United States market, brand recognition of Tristel $^{\text{IM}}$ ULT has grown rapidly, and this case study will accelerate our progress further."

For further information please contact:

Tristel plc

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

Tel: 01638 721 500

www.investors.tristel.com

Walbrook PR Ltd Tel: 020 7933 8780 or

Paul McManus Mob: 07980 541 893
Alice Woodings Mob: 07407 804 654

Tel: 020 7220 0500

Cavendish Capital Markets Ltd

Geoff Nash / Charlie Beeson (Corporate Finance) Sunila de Silva (ECM)

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the <u>Tristel</u> brand, and under the <u>Cache</u> brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com